Olga Samoilova
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research 9
-
- Lymphoma Diagnosis and Treatment 10
- Hematology top 5%
- Multiple Myeloma Research and Treatments 7
- Chronic Myeloid Leukemia Treatments 4
- Oncology top 10%
- Viral-associated cancers and disorders 3
- Vascular Tumors and Angiosarcomas 1
-
- T-cell and Retrovirus Studies 2
-
- Protein Degradation and Inhibitors 4
- Co-authors
- Helgi van de VeldeJan NovákEvgenii A. OsmanovFatih DemırkanFong ClowCarol MorenoMartin ŠimkovičDanelle F. James
- Partner nations
- RussiaUnited StatesUnited Kingdom
In The Last Decade
Olga Samoilova
20 papers receiving 893 citations
Hit Papers
Peers
Comparison fields: 5 of 50
- Genetics 574
- Pathology and Forensic Medicine 634
- Hematology 254
- Oncology 388
- Immunology 179
Countries citing papers authored by Olga Samoilova
This map shows the geographic impact of Olga Samoilova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olga Samoilova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olga Samoilova more than expected).
Fields of papers citing papers by Olga Samoilova
This network shows the impact of papers produced by Olga Samoilova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olga Samoilova. The network helps show where Olga Samoilova may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Olga Samoilova, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 3 | |
| 2 | 2022 | 4 | |
| 3 | 2020 | 8 | |
| 4 | 2019 | 3 | |
| 5 | 2019 | 3 | |
| 6 | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialbreakdown → | 2018 | 380 |
| 7 | 2018 | 14 | |
| 8 | 2018 | 7 | |
| 9 | 2018 | 36 | |
| 10 | 2018 | 13 | |
| 11 | 2017 | 1 | |
| 12 | 2017 | 9 | |
| 13 | 2016 | 1 | |
| 14 | 2015 | 98 | |
| 15 | 2015 | 261 | |
| 16 | 2014 | 3 | |
| 17 | 2014 | 5 | |
| 18 | 2012 | 16 | |
| 19 | 2009 | 8 | |
| 20 | 2007 | 39 |
About Olga Samoilova
Olga Samoilova is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine, having authored 20 papers that have together received 912 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (10 papers), Chronic Lymphocytic Leukemia Research (9 papers), Multiple Myeloma Research and Treatments (7 papers), Chronic Myeloid Leukemia Treatments (4 papers), Protein Degradation and Inhibitors (4 papers), Viral-associated cancers and disorders (3 papers), T-cell and Retrovirus Studies (2 papers) and Vascular Tumors and Angiosarcomas (1 paper). The work is most often cited by research in Genetics (574 citations), Pathology and Forensic Medicine (634 citations) and Hematology (254 citations). Olga Samoilova has collaborated with scholars based in Russia, United States and United Kingdom. Frequent co-authors include Helgi van de Velde, Jan Novák, Evgenii A. Osmanov, Fatih Demırkan, Fong Clow, Carol Moreno, Martin Šimkovič, Danelle F. James, Владимир Стругов and John G. Gribben. Their work appears in journals such as Blood, Journal of Clinical Oncology, Pharmaceutical Research, Acta Haematologica and HemaSphere.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.